Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice

Pharmacogenomics Journal

Volumn 12, Issue 2, 2012, Pages 147-155

  Crowley, J J ^a,b   Adkins, D E ^c   Pratt, A L ^a   Quackenbush, C R ^a   Van Den Oord, E J ^c   Moy, S S ^a   Wilhelmsen, K C ^b   Cooper, T B ^d   Bogue, M A ^e   McLeod, H L ^b   Sullivan, P F ^a,f  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^e JACKSON LABORATORY   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

adverse drug reaction; antipsychotic; haloperidol; mouse model; tardive dyskinesia; vacuous chewing movements

Indexed keywords

NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE LOCUS; GENE MAPPING; GENETIC ANALYSIS; GENETIC ASSOCIATION; HERITABILITY; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; HALOPERIDOL; MALE; MASTICATION; MICE; MICE, INBRED STRAINS;

ANIMALIA; MURINAE; MUS;

EID: 84859000413     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.82     Document Type: Article

References (34)

1. Harrill AH, Watkins PB, Su S, Ross PK, Harbourt DE, Stylianou IM et al. Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res 2009; 19: 1507-1515.
2. Yang H, Ding Y, Hutchins LN, Szatkiewicz J, Bell TA, Paigen BJ et al. A customized and versatile high-density genotyping array for the mouse. Nat Methods 2009; 6: 663-666.
3. Simpson GM. Long-acting, antipsychotic agents and extrapyramidal side effects. Dis Nerv Syst 1970; 31(Suppl): 12-14.
4. Dayalu P, Chou KL. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother 2008; 9: 1451-1462. (Pubitemid 352005909)
5. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol 2007; 27: 159-169. (Pubitemid 46564477)
6. Crane GE. Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature. Am J Psychiatry 1968; 124(Suppl): 40-48.
7. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 2006; 83: 185-192.
8. Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999; 21: 17-27. (Pubitemid 29253832)
9. Basile VS, Ozdemir V, Masellis M, Meltzer HY, Lieberman JA, Potkin SG et al. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry 2001; 6: 230-234. (Pubitemid 32187876)
10. de Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005; 25: 448-456. (Pubitemid 41368367)
11. Eichhammer P, Albus M, Borrmann-Hassenbach M, Schoeler A, Putzhammer A, Frick U et al. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen0s study on DRD3 and tardive dyskinesia. Am J Med Genet 2000; 96: 187-191. (Pubitemid 30180861)
12. Patsopoulos NA, Ntzani EE, Zintzaras E, Ioannidis JP. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics 2005; 15: 151-158. (Pubitemid 40569901)
13. Turrone P, Remington G, Nobrega JN. The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neurosci Biobehav Rev 2002; 26: 361-380. (Pubitemid 34553319)
14. Hsin-Tung E, Simpson G. Medication-induced movement disorders. In: Kaplan HI, Sadock BJ (eds). Comprehensive Textbook of Psychiatry. Lippincott Williams and Wilkins: Philadephia, PA, 2000, pp 2265-2270.
15. Fleischmann N, Christ G, Sclafani T, Melman A. The effect of ovariectomy and long-term estrogen replacement on bladder structure and function in the rat. J Urol 2002; 168: 1265-1268.
16. Tomiyama K, McNamara FN, Clifford JJ, Kinsella A, Koshikawa N, Waddington JL. Topographical assessment and pharmacological characterization of orofacial movements in mice: dopamine D(1)-like vs. D(2)-like receptor regulation. Eur J Pharmacol 2001; 418: 47-54. (Pubitemid 32378809)
17. Crawley JN. Exploratory behavior models of anxiety in mice. Neurosci Biobehav Rev 1985; 9: 37-44. (Pubitemid 15136669)
18. Barnes DE, Robinson B, Csernansky JG, Bellows EP. Sensitization versus tolerance to haloperidol-induced catalepsy: multiple determinants. Pharmacol Biochem Behav 1990; 36: 883-887. (Pubitemid 20272310)
19. Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 2004; 61: 310-317. (Pubitemid 38295833)
20. Goldstein H. Multilevel statistical models. In: Searle S, Casella G, McCulloch C (eds) Variance Components. Wiley: New York, 1995.
21. Joreskog K. A general approach to confirmatory maximum likelihood factor analysis. Psychometrika 1969; 34: 183-202.
22. Muthén B, Muthén L. Traditional Latent Variable Modeling Using Mplus. Mplus Short Course Notes: Los Angeles, CA, 2003.
23. Van Prooijen J, Van Der Kloot WA. Confirmatory analysis of exploratively obtained factor structures. Educ Psychol Meas 2001; 51: 777-792. (Pubitemid 33398006)
24. Baile JS, Grabowski-Boas L, Steff BM, Wiltshire T, Churchil GA, Tarantino LM. Identification of quantitative trait loci for locomotor activation and anxiety using closely related inbred strains. Genes Brain Behav 2008; 7: 761-769.
25. Kas MJ, de Mooij-van Malsen JG, de Krom M, van Gassen KL, van Lith HA, Olivier B et al. High-resolution genetic mapping of mammalian motor activity levels in mice. Genes Brain Behav 2009; 8: 13-22.
26. Crocker L, Algina J. Introduction to Classical and Modern Test Theory. Wadsworth Publishing: New York, 1986.
27. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003; 305: 625-631. (Pubitemid 36459179)
28. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223. (Pubitemid 41345943)
29. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-487. (Pubitemid 12152819)
30. Miller D, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005; 80: 33-43. (Pubitemid 41587461)
31. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW Publication No. ADM 534-537). US Department of Health, Education, and Welfare: Bethesda, MD, 1976.
32. Tracy K, Adler LA, Rotrosen J, Edson R, Lavori P. Interrater reliability issues in multicenter trials, Part I: Theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study #394. Psychopharmacol Bull 1997; 33: 53-57.
33. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-676. (Pubitemid 19154942)
34. Chadman KK, Yang M, Crawley JN. Criteria for validating mouse models of psychiatric diseases. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 1-11.